Oncotelic Therapeutics (OTLC) awards 250 RSUs tied to uplisting milestone
Rhea-AI Filing Summary
Fein Seymour Howard reported acquisition or exercise transactions in this Form 4 filing.
Oncotelic Therapeutics, Inc. granted its CRO/CMO, Seymour Howard Fein, 250 restricted stock units on July 10, 2026. Each RSU will settle into one share of Series A Convertible Preferred Stock, and each preferred share is convertible into 1,000 common shares, contingent on performance and time-based vesting. Vesting requires an uplisting of the common stock to a national securities exchange by June 30, 2027 (or a later Board-approved date) and six months of continued service after the uplisting.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Fein Seymour Howard
Role
CRO/CMO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted stock Units F1, F2 | 250 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted stock Units — 250 shares (Direct)
Footnotes (2)
- F1. On July 10, 2026, the reporting person was granted 250 restricted stock units ("RSUs"), subject to performance and time-based vesting. On vesting each RSU will immediately be settled by delivery of, and each RSU represents the contingent right to receive, one share of the issuer's Series A Convertible Preferred Stock, par value $0.01. Each share of Series A Convertible Preferred Stock, in turn, is convertible into 1,000 shares of the issuer's common stock, par value $0.01 per share.
- F2. The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting.
Key Figures
RSUs granted: 250 units
Preferred-to-common conversion ratio: 1,000 shares of common stock per preferred share
Potential common shares: 250,000 shares of common stock
+2 more
5 metrics
RSUs granted
250 units
Restricted stock units granted to CRO/CMO Seymour Howard Fein on July 10, 2026
Preferred-to-common conversion ratio
1,000 shares of common stock per preferred share
Each share of Series A Convertible Preferred Stock is convertible into 1,000 common shares
Potential common shares
250,000 shares of common stock
Maximum common shares if 250 RSUs vest and resulting preferred shares are fully converted
Uplisting deadline for vesting
June 30, 2027
Uplisting to a national securities exchange must occur by this date, unless the Board extends it
Par value of preferred stock
$0.01 per share
Par value of the issuer's Series A Convertible Preferred Stock underlying the RSUs
Key Terms
restricted stock units, Series A Convertible Preferred Stock, performance and time-based vesting, uplisting, +1 more
5 terms
restricted stock units financial
"the reporting person was granted 250 restricted stock units ("RSUs"), subject"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Series A Convertible Preferred Stock financial
"one share of the issuer's Series A Convertible Preferred Stock, par value $0.01"
Series A convertible preferred stock is a class of shares sold in an early funding round that gives investors a mix of protection and upside: it pays a priority claim over common shares if the company is sold or closes, but can be converted into ordinary shares to share in future growth. Think of it like a hybrid between a safer stake and a ticket to ownership; it matters to investors because it affects who controls the company, how future gains are split, and how much their investment is protected from downside.
performance and time-based vesting financial
"250 restricted stock units ("RSUs"), subject to performance and time-based vesting."
uplisting market
"The RSU's will vest upon (a) achievement of an uplisting of the issuer's"
Uplisting occurs when a company's stock moves from a less regulated, smaller exchange to a more established and widely recognized one. This transition can make the stock more accessible and attractive to a broader range of investors, potentially increasing its value and trading volume. For investors, uplisting often signals growth and stability, which can influence confidence and trading decisions.
national securities exchange regulatory
"uplisting of the issuer's common stock to a national securities exchange on or"
A national securities exchange is a regulated marketplace where buyers and sellers trade stocks, bonds and other securities and where companies meet requirements to have their shares available to the public. It matters to investors because the exchange enforces rules, provides transparent prices and a steady flow of buyers and sellers—like a supervised marketplace that helps ensure fair pricing, easier buying and selling, and basic investor protections.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Oncotelic Therapeutics (OTLC) grant to Seymour Howard Fein?
On July 10, 2026, Oncotelic Therapeutics granted its CRO/CMO, Seymour Howard Fein, 250 restricted stock units (RSUs). Each RSU entitles him, upon vesting, to one share of Series A Convertible Preferred Stock, which is further convertible into common shares.
What are the vesting conditions for the 250 RSUs at Oncotelic Therapeutics (OTLC)?
The 250 RSUs vest only if the company’s common stock is uplisted to a national securities exchange by June 30, 2027 (or a later Board-approved date) and Seymour Fein remains in service for six months after the uplisting.
What stock underlies the RSU award reported by Oncotelic Therapeutics (OTLC)?
Each RSU corresponds to one share of Series A Convertible Preferred Stock, par value $0.01 per share. Each preferred share is, in turn, convertible into 1,000 shares of the company’s common stock, also with a par value of $0.01 per share.
How is the uplisting event linked to the OTLC RSU vesting?
The RSUs vest only upon uplisting the company’s common stock to a national securities exchange by June 30, 2027 (or a later date the Board approves), followed by six months of continued service by Seymour Fein after that uplisting event.